Analysis of Methylation of Tumor-suppressive miRNAs and KRAS/TP53 Mutations in Pancreatic Juice.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-12-01 DOI:10.21873/anticanres.17353

Koushiro Ohtsubo, Kunio Miyake, Shigeki Sato, Hiroyuki Sakaguchi, Koji Fukuda, Hiroshi Kotani, Akihiro Nishiyama, Shigeki Nanjo, Kaname Yamashita, Shinji Takeuchi, Seiji Yano, Sawako Kuruma, Jun Nakahodo, Masataka Kikuyama, Hiroaki Taniguchi

{"title":"Analysis of Methylation of Tumor-suppressive miRNAs and KRAS/TP53 Mutations in Pancreatic Juice.","authors":"Koushiro Ohtsubo, Kunio Miyake, Shigeki Sato, Hiroyuki Sakaguchi, Koji Fukuda, Hiroshi Kotani, Akihiro Nishiyama, Shigeki Nanjo, Kaname Yamashita, Shinji Takeuchi, Seiji Yano, Sawako Kuruma, Jun Nakahodo, Masataka Kikuyama, Hiroaki Taniguchi","doi":"10.21873/anticanres.17353","DOIUrl":null,"url":null,"abstract":"Background/aim: We previously reported the usefulness of detecting aberrant methylation in tumor suppressive microRNAs (miRNAs) in bile and plasma to discriminate pancreaticobiliary cancers from benign pancreaticobiliary diseases. This study analyzed the methylation of miRNAs in pancreatic juice to identify those specific to pancreatic cancer (PC).Patients and methods: Pancreatic juice was collected from 20 patients with PC, including eight with intraductal papillary mucinous carcinoma (IPMC), two with low grade-pancreatic intraepithelial neoplasia (LG-PanIN), 32 with LG-intraductal papillary mucinous neoplasm (IPMN), and seven with benign pancreatic lesions. Polymerase chain reaction amplification and sequencing were performed for three tumor suppressive miRNAs (miR-200a, 200b, and 1247), and their methylation rates were determined. Additionally, KRAS and TP53 mutations were analyzed.Results: The methylation rate of miR-1247 was significantly higher in patients with PC than in those with LG-PanIN/IPMN. Furthermore, it was significantly higher in patients with IPMC than in those with LG-IPMN. KRAS and TP53 mutations were detected in seven (70%) and one (10%) of the patients with PC, respectively.Conclusion: Analyzing the methylation of miR-1247 in addition to KRAS and TP53 mutations in pancreatic juice may be useful to distinguish PC from PanIN/IPMN.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5253-5261"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17353","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: We previously reported the usefulness of detecting aberrant methylation in tumor suppressive microRNAs (miRNAs) in bile and plasma to discriminate pancreaticobiliary cancers from benign pancreaticobiliary diseases. This study analyzed the methylation of miRNAs in pancreatic juice to identify those specific to pancreatic cancer (PC).

Patients and methods: Pancreatic juice was collected from 20 patients with PC, including eight with intraductal papillary mucinous carcinoma (IPMC), two with low grade-pancreatic intraepithelial neoplasia (LG-PanIN), 32 with LG-intraductal papillary mucinous neoplasm (IPMN), and seven with benign pancreatic lesions. Polymerase chain reaction amplification and sequencing were performed for three tumor suppressive miRNAs (miR-200a, 200b, and 1247), and their methylation rates were determined. Additionally, KRAS and TP53 mutations were analyzed.

Results: The methylation rate of miR-1247 was significantly higher in patients with PC than in those with LG-PanIN/IPMN. Furthermore, it was significantly higher in patients with IPMC than in those with LG-IPMN. KRAS and TP53 mutations were detected in seven (70%) and one (10%) of the patients with PC, respectively.

Conclusion: Analyzing the methylation of miR-1247 in addition to KRAS and TP53 mutations in pancreatic juice may be useful to distinguish PC from PanIN/IPMN.

查看原文本刊更多论文

胰液中肿瘤抑制mirna的甲基化和KRAS/TP53突变分析。

背景/目的：我们之前报道了检测胆汁和血浆中肿瘤抑制microRNAs （miRNAs）异常甲基化的有效性，以区分胰腺胆道癌和良性胰腺胆道疾病。本研究分析了胰腺液中mirna的甲基化，以鉴定胰腺癌（PC）特异性mirna。患者和方法：收集20例PC患者的胰液，其中8例导管内乳头状粘液癌（IPMC）， 2例低级别胰腺上皮内瘤变（LG-PanIN）， 32例导管内乳头状粘液瘤（IPMN）， 7例胰腺良性病变。对三个肿瘤抑制mirna （miR-200a、200b和1247）进行聚合酶链反应扩增和测序，并测定其甲基化率。此外，还分析了KRAS和TP53突变。结果：PC患者miR-1247的甲基化率明显高于LG-PanIN/IPMN患者。此外，IPMC患者的血压明显高于LG-IPMN患者。KRAS和TP53突变分别在7例（70%）和1例（10%）PC患者中检测到。结论：分析胰液中miR-1247的甲基化以及KRAS和TP53突变可能有助于区分PC与PanIN/IPMN。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.